15. Cutter NC, Scott DD, Johnson JC, Whiteneck 30. Jarrett L, Nandi P, Thompson AJ. Managing se- G. Gabapentin effect on spasticity in multiple vere lower limb spasticity in multiple sclerosis: 1. Abrams P. Evidence for the efficacy and safety sclerosis: a placebo-controlled, randomized does intrathecal phenol have a role? J Neurol of tolterodine in the treatment of overactive trial. Arch Phys Med Rehabil 2000; 81: 164-9.
Neurosurg Psychiatry 2002; 73: 705-9.
bladder. Expert Opin Pharmacother 2001; 2: 16. DasGupta R, Fowler CJ. Bladder, bowel and 31. Kesselring J, Thompson AJ. Spasticity, ataxia sexual dysfunction in multiple sclerosis. Mana- and fatigue in multiple sclerosis. Baillière’s Clin 2. Albrecht H, Schwecht M, Pöllmann W, Parag D, gement strategies. Drugs 2003; 63: 153-66.
Erasmus L-P, König N. Klinischer Nachweis 17. Dietz V, Young RR. The syndrome of spastic 32. Killestein J, Hoogervorst ELJ, Reif M, Kalkers positiver Behandlungseffekte bei Patienten paresis. In: Brandt T, Dichgans J (eds). Neuro- NF, van Loenen AC, Staats PGM, Gorter RW, mit multipler Sklerose. Nervenarzt 1998; 69: logical Disorders: Course and treatment. New Uitdehaag BMJ, Polman CH. Safety, tolerabil- ity and efficacy of orally administered cannabi- 3. Appel RA, Sand P, Dmochowski R, Anderson 18. Dula E, Bukofzer S, Perdok R, George M, and noids in MS. Neurology 2002; 58: 1404-7.
R, Zinner N, Lama D, Roach M, Miklos J, Saltz- 33. Krogh K, Christensen P, Laurberg S. Colorectal stein D, Boone T, Staskin DR, Albrecht D for blind, crossover comparison of 3 mg apomor- symptoms in patients with neurological disease.
the Object Study Group. Prospective randomi- phine SL with placebo and with 4 mg apomor- Acta Neurol Scand 2001; 103: 335-43.
zed controlled trial of extended-release oxybu- phine SL in male erectile dysfunction. Eur Urol 34. Krupp LB, Coyle PK, Doscher C, Miller A, tynin chloride and tolterodine tartrate in the Cross AH, Jandorf L, Halper J, Johnson B, Mor- treatment of overactive bladder: results of 19. Fernández O. Mechanisms and current treat- gante L, Grimson R. Fatigue therapy in mul- the OBJECT Study. Mayo Clin Proc 2001; 76: ments of urogenital dysfunction in multiple tiple sclerosis: results of a double-blind, random- ized, parallel trial of amantadine, pemoline and 4. Baker D, Pryce G, Croxford JL, Brown P, Pert- 20. Flachenecker P, Kümpfel T, Kallmann B, Gott- placebo. Neurology 1995; 45: 1956-61.
schalk M, Grauer O, Rieckmann P,Trenkwalder 35. Kurtzke JF. Rating neurological impairment in noids control spasticity and tremor in a multi- C, Toyka KV. Fatigue in multiple sclerosis: a multiple sclerosis: an expanded disability status ple sclerosis model. Nature 2000; 404: 84-7.
comparison of different rating scales and corre- scale (EDSS). Neurology 1983; 33: 1444-52.
5. Bayas A, Rieckmann P. Managing the adverse lation to clinical parameters. Mult Scler 2002; 36. Lublin FD, Whitaker JN, Eidelman BH, Miller effects of interferon-β therapy in multiple sclerosis. Drug Safety 2000; 22: 149-59.
21. Fowler CJ. Neurological disorders of mictu- patients receiving interferon beta-1b for mul- 6. Betts CD, Jones SJ, Fowler CG, Fowler CJ.
rition and their treatment. Brain 1999; 122: tiple sclerosis: report of a consensus conference.
Erectile dysfunction in multiple sclerosis: asso- ciated neurological and neurophysiological 22. Fowler C, Miller J, Sharief M for the Sildena- 37. Mertin J. Symptomatische Behandlung. In: Kes- deficits, and treatment of the condition. Brain fil Study Group. Viagra (sildenafil citrate) for selring J (Hrsg). Multiple Sklerose. 3. Auflage.
the treatment of erectile dysfunction in men Stuttgart: Kohlhammer 1997; 199-214.
7. Bramanti P, Sessa E, Rifici C, D´Aleo G, Flori- with multiple sclerosis. Ann Neurol 1999; 46: 38. Metz L. Multiple sclerosis: symptomatic thera- dia D, Di Bella P, Lublin F. Enhanced spasticity pies. Semin Neurol 1998; 18: 389-95.
in primary progressive MS patients treated 23. Gold R, Toyka KV. Immuntherapie neurologi- 39. Morris K. Melanocortins key to trigger sex on with interferon beta-1b. Neurology 1998; 51: the brain. The Lancet Neurology 2003; 2: 140.
40. MS-Therapie Konsensus Gruppe (MSTKG).
8. Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde 24. Gracies J-M, Elovic E, McGuire J, Simpson D.
C. Treatments for fatigue in multiple sclerosis: a Traditional pharmacological treatments for rapid and systematic review. Health Technol spasticity. Part II: General and regional treat- ments. Muscle Nerve 1997; Suppl 6: S92-S120.
41. Mueller ME, Gruenthal M, Olson WL, Olson 9. Brar SP, Smith MB, Nelson LM, Franklin GM, 25. Hartung H-P, Gonsette R, König N, Kwiecinski WH. Gabapentin for relief of upper motor neu- Cobble ND. Evaluation of treatment protocols H, Guseo A, Morrissey SP, Krapf H, Zwingers ron symptoms in multiple sclerosis. Arch Phys on minimal to moderate spasticity in multiple T, and the Mitoxantrone in Multiple Sclerosis sclerosis. Arch Phys Med Rehabil 1991; 72: 42. Müller-Lissner SA. Effect of wheat bran on gressive multiple sclerosis: a placebo-con- weight of stool and gastrointestinal transit 10. Caruso S, Intelisano G, Lupo L Agnello C. Pre- trolled, double-blind, randomised, multicentre time: a meta analysis. Br Med J 1988; 296: 615-7.
menopausal women affected by sexual arousal 43. Multiple Sklerose-Therapie-Konsensus-Grup- disorder treated with sildenafil: a double-blind, 26. Hilton P, Hertogs K, Stanton SL. The use of cross-over, placebo-controlled study. Br J Obs- desmopressin (DDAVP) for nocturia in women fentherapie der multiplen Sklerose, 1. Er- with multiple sclerosis. J Neurol Neurosurg gänzung: Dezember 2000. Nervenarzt 2001; 72: 11. Clanet MG, Brassat D. The management of multiple sclerosis patients. Curr Opin Neurol 27. Hulter BM, Lundberg PO. Sexual function 44. Multiple-Sklerose-Therapie-Konsensus-Grup- in women with advanced multiple sclerosis.
pe. Immunmodulatorische Stufentherapie der 12. Colombo B, Martinelli Boneschi F, Rossi P, Ro- J Neurol Neurosurg Psychiatry 1995; 59: 83-6.
Multiplen Sklerose, Neue Aspekte und prakti- varis M, Maderna L, Filippi M, Comi C. MRI 28. Hyman N, Barnes M, Bhakta B, Cozens A, Bak- sche Umsetzung, März 2002. Nervenarzt 2002; and motor evoked potential findings in nondis- heit M, Kreczy-Kleedorfer B, Poewe W, Wissel abled multiple sclerosis patients with and with- J, Bain P, Glickman S, Sayer A, Richardson A, 45. Nance PW, Sheremata WA, Lynch SG, Vollmer out symptoms of fatigue. J Neurol 2000; 247: Dott C. Botulinum toxin (Dysport®) treatment T, Hudson S, Francis GS, O´Connor P, Cohen of hip adductor spasticity in multiple sclerosis: JA, Schapiro RT, Whitham R, Mass MK, Lind- 13. Comi G, Leocani L, Rossi P, Colombo B. Phy- a prospective, randomised, double blind, place- sey JW, Shellenberger K. Relationship of the siopathology and treatment of fatigue in multi- bo controlled, dose ranging study. J Neurol antispasticity effect of tizanidine to plasma con- ple sclerosis. J Neurol 2001; 248: 174-9.
Neurosurg Psychiatry 2000; 68: 707-12.
centration in patients with multiple sclerosis.
14. Corbin JD, Francis SH, Webb DJ. Phospho- 29. Janardhan V, Bakshi R. Quality of life in pa- diesterase type 5 as a pharmacologic target in tients with multiple sclerosis: the impact of 46. Ochs G, Struppler A, Meyerson BA, Linderoth erectile dysfunction. Urology 2002; 60 (Suppl fatigue and depression. J Neurol Sci 2002; 205: B, Gybels J, Gardner BP, Teddy P, Jamous A, Weinmann P. Intrathecal baclofen for long- term treatment of spasticity: a multi-centre A, Dellas S, Maguire RP, Missimer J, Radü EW, pyridine in the treatment of fatigue in multiple study. J Neurol Neurosurg Psychiatry 1989; 52: Steck A, Leenders KL. Reduced glucose meta- bolism in the frontal cortex and the basal 61. The United Kingdom Tizanidine Trial Group.A 47. Padma-Nathan H, Eardley I, Kloner RA, La- ganglia of multiple sclerosis patients with fati- double-blind, placebo-controlled trial of tiza- ties AM, Montorsi F. A 4-year update on the gue: a 18F-fluorodeoxyglucose positron emis- nidine in the treatment of spasticity caused by safety of sildenafil citrate (Viagra®). Urology sion tomography study. Neurology 1997; 48: multiple sclerosis. Neurology 1994; 44 (Suppl 48. Padma-Nathan H, Hellstrom WJG, Kaiser FE, 54. Rossini PM, Pasqualetti P, Pozzilli C, Grasso 62. Valiquette G, Herbert J, Meade-D´Alisera P.
Labasky RF, Lue TF, Nolten WE, Norwood PC, MG, Millefiorini E, Graceffa A, Carlesimo GA, Desmopressin in the management of nocturia Peterson CA, Shabsigh R, Tam PY, Place VA, Zibellini G, Caltagirone C. Fatigue in progressi- in patients with multiple sclerosis. A double- Gesundheit N for the Medical Urethral Sys- ve multiple sclerosis: results of a randomized, blind, crossover trial. Arch Neurol 1996; 53: tem For Erection (MUSE) Study Group. Treat- double-blind, placebo-controlled, crossover ment of men with erectile dysfunction with trial of oral 4-aminopyridine. Mult Scler 2001; 63. Weinshenker BG, Penman M, Bass B, Ebers transurethral alprostadil. N Engl J Med 1997; GC, Rice GPA. A double-blind, randomized, 55. Sampson FC, Hayward A, Evans G, Morton R, crossover trial of pemoline in fatigue associated 49. Paisley S, Beard S, Hunn A, Wight J. Clinical Collett B. Functional benefits and cost/benefit with multiple sclerosis. Neurology 1992; 42: effectiveness of oral treatments for spasticity in analysis of continous intrathecal baclofen infu- multiple sclerosis: a systematic review. Mult sion for the management of severe spasticity.
64. Wiesel PH, Norton C, Roy AJ, Storrie JB, Bo- 50. Penn RD, Savoy SM, Corcos D, Latash M, 56. Schapiro RT. Management of spasticity, pain, treatment (biofeedback) for constipation and Gottlieb G, Parke B, Kroin JS. Intrathecal bac- and paroxysmal phenomena in multiple sclero- faecal incontinence in multiple sclerosis. J Neu- lofen for severe spinal spasticity. N Engl J Med sis. Curr Neurol Neurosci Rep 2001; 1: 299-302.
rol Neurosurg Psychiatry 2000; 69: 240-3.
57. Schapiro RT. Pharmacological options for 65. Zifko UA, Rupp M, Schwarz S, Zipko HT, 51. Polman CH, Bertelsmann FW, de Waal R, van the management of multiple sclerosis symp- Maida EM. Modafinil in treatment of fatigue toms. Neurorehabil Neural Repair 2002; 16: in multiple sclerosis. Results of an open-label AC, Koetsier JC. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of pa- 58. Schwid SR, Covington M, Segal BM, Goodman 66. Zimmermann C, Hohlfeld R. “Fatigue” bei tients with multiple sclerosis. Arch Neurol AD. Fatigue in multiple sclerosis: current un- multipler Sklerose. Nervenarzt 1999; 70: 566-74.
derstanding and future directions. J Rehabil 67. Zorzon M, Zivadinov R, Bosco A, Monti Bra- 52. Rammohan KW, Rosenberg JH, Lynn DJ, Blu- gadin L, Moretti R, Bonfigli L, Morassi P, Iona menfeld AM, Pollak CP, Nagaraja HN. Efficacy 59. Shakespeare DT, Boggild M, Young C. Anti- LG, Cazzato G. Sexual dysfunction in multiple and safety of modafinil (Provigil®) for the spasticity agents for multiple sclerosis (Coch- sclerosis: a case-control study. I. Frequency and treatment of fatigue in multiple sclerosis: a two rane Review). The Cochraine Library, Issue 1.
comparison of groups. Mult Scler 1999; 5: centre phase 2 study. J Neurol Neurosurg Psy- 60. Sheean GL, Murray NMF, Rothwell JC, Miller 53. Roelcke U, Kappos L, Lechner-Scott J, Brunn- DH, Thompson AJ. An open-labelled clinical and electrophysiological study of 3,4 diamino-


Microsoft word - necessary medication packing list

GMB Medication List The following numbers are estimates of the amount of medications dispensed during a brigade. It is always a good idea to plan for a larger brigade because if the medications are not all distributed on a brigade, WE WILL FIND A USE FOR THEM. We are active all year long, and can always use them later. Vitamins:  Children's infant vitamins  A

Power of attorney (real estate)

POWER OF ATTORNEY (REAL ESTATE) IMPORTANT INFORMATION This power of attorney authorizes another person (your agent) to make decisions for you(the principal) and to act on your behalf concerning your real property. You should selectsomeone you trust to serve as your agent. Unless you specify otherwise, generally the agent’s authority will continue until you die orrevoke the power of

Copyright © 2010-2014 Drug Shortages pdf